Please use this identifier to cite or link to this item: http://dx.doi.org/10.18419/opus-1908
Authors: Bucher, Joachim
Riedmaier, Stephan
Schnabel, Anke
Marcus, Katrin
Vacun, Gabriele
Weiss, Thomas S.
Thasler, Wolfgang E.
Nüssler, Andreas K.
Zanger, Ulrich M.
Reuss, Matthias
Title: A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes
Issue Date: 2011
metadata.ubs.publikation.typ: Zeitschriftenartikel
metadata.ubs.publikation.source: BMC Systems Biology 5 (2011), Nr. 66. URL http://dx.doi.org./10.1186/1752-0509-5-66
URI: http://nbn-resolving.de/urn:nbn:de:bsz:93-opus-63606
http://elib.uni-stuttgart.de/handle/11682/1925
http://dx.doi.org/10.18419/opus-1908
metadata.ubs.bemerkung.extern: Vollständige Lizenzbedingungen siehe: <a href="http://www.biomedcentral.com/info/authors/license">http://www.biomedcentral.com/info/authors/license</a>
Abstract: Background The individual character of pharmacokinetics is of great importance in the risk assessment of new drug leads in pharmacological research. Amongst others, it is severely influenced by the properties and inter-individual variability of the enzymes and transporters of the drug detoxification system of the liver. Predicting individual drug biotransformation capacity requires quantitative and detailed models. Results In this contribution we present the de novo deterministic modeling of atorvastatin biotransformation based on comprehensive published knowledge on involved metabolic and transport pathways as well as physicochemical properties. The model was evaluated on primary human hepatocytes and parameter identifiability analysis was performed under multiple experimental constraints. Dynamic simulations of atorvastatin biotransformation considering the inter-individual variability of the two major involved enzymes CYP3A4 and UGT1A3 based on quantitative protein expression data in a large human liver bank (n = 150) highlighted the variability in the individual biotransformation profiles and therefore also points to the individuality of pharmacokinetics. Conclusions A dynamic model for the biotransformation of atorvastatin has been developed using quantitative metabolite measurements in primary human hepatocytes. The model comprises kinetics for transport processes and metabolic enzymes as well as population liver expression data allowing us to assess the impact of inter-individual variability of concentrations of key proteins. Application of computational tools for parameter sensitivity analysis enabled us to considerably improve the validity of the model and to create a consistent framework for precise computer-aided simulations in toxicology.
Appears in Collections:04 Fakultät Energie-, Verfahrens- und Biotechnik

Files in This Item:
File Description SizeFormat 
1752_0509_5_66.pdfFull text654,86 kBAdobe PDFView/Open
Additional_file_1.pdfAdditional file 128,15 kBAdobe PDFView/Open
Additional_file_2.pdfAdditional file 218,36 kBAdobe PDFView/Open
Additional_file_3.pdfAdditional file 311,66 kBAdobe PDFView/Open
Additional_file_4.pdfAdditional file 4178,79 kBAdobe PDFView/Open
Additional_file_5.pdfAdditional file 59,46 kBAdobe PDFView/Open
Additional_file_6.pdfAdditional file 69,63 kBAdobe PDFView/Open


Items in OPUS are protected by copyright, with all rights reserved, unless otherwise indicated.